Sign in or create an account to add this stock to your watchlist.
About Soleno Therapeutics (NASDAQ:SLNO)
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces. In addition, the company offers Serenz, a handheld device that delivers non-inhaled carbon dioxide topically to the nasal mucosa. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444
Debt
Debt-to-Equity RatioN/A
Current Ratio8.14
Quick Ratio8.14
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.45 million
Price / Sales28.63
Cash FlowN/A
Price / CashN/A
Book Value$1.16 per share
Price / Book1.81
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-54.36%
Return on Assets-40.91%
Miscellaneous
Employees18
Outstanding Shares19,770,000
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Soleno Therapeutics's stock reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics (NASDAQ:SLNO) announced its earnings results on Wednesday, May, 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
2 analysts have issued 12 month price objectives for Soleno Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Soleno Therapeutics' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Soleno Therapeutics.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Second Sight Medical Products (EYES), Biolife Solutions (BLFS), Zynex (ZYXI), IRIDEX (IRIX), Edap Tms (EDAP), Semler Scientific (SMLR), BioSig Technologies (BSGM), Viveve Medical (VIVE), Stereotaxis (STXS), Digirad (DRAD), Dynatronics (DYNT), Nexeon MedSystems (NXNN), Aradigm (ARDM), CHF Solutions (CHFS) and Reshape Lifesciences (RSLS).
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 48)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
- Mr. David D. O'Toole, Consultant (Age 59)
- Mr. Jonathan R. Wolter, Interim Chief Financial Officer (Age 68)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Has Soleno Therapeutics been receiving favorable news coverage?
News coverage about SLNO stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Soleno Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned press coverage about the company an impact score of 48.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $2.10.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $38.55 million and generates $1.45 million in revenue each year. Soleno Therapeutics employs 18 workers across the globe.
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Soleno Therapeutics (NASDAQ:SLNO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Soleno Therapeutics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 90.48%. The high price target for SLNO is $4.00 and the low price target for SLNO is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | $25.00 |
| Price Target Upside: | 90.48% upside | 138.10% upside | 143.90% upside | 872.76% upside |
Soleno Therapeutics (NASDAQ:SLNO) Consensus Price Target History
Soleno Therapeutics (NASDAQ:SLNO) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Soleno Therapeutics (NASDAQ:SLNO) Earnings History and Estimates Chart
Soleno Therapeutics (NASDAQ SLNO) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2018 | | | | | | | N/A |  |
| 5/16/2018 | Q1 2018 | ($0.09) | ($0.17) | | | View | N/A | |
| 4/2/2018 | Q4 2017 | | ($0.39) | | | View | N/A | |
| 11/14/2017 | Q3 2017 | | ($0.24) | | | View | N/A | |
| 8/11/2017 | Q2 2017 | ($0.40) | ($0.30) | | | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.35) | ($0.55) | | $0.27 million | View | N/A | |
| 3/15/2017 | Q4 2016 | ($1.15) | ($0.82) | | $0.28 million | View | N/A | |
| 11/14/2016 | Q3 2016 | | ($2.05) | | $0.33 million | View | N/A | |
| 8/12/2016 | Q2 | ($1.00) | ($1.15) | | $0.39 million | View | N/A | |
| 5/10/2016 | Q115 | ($1.35) | ($1.10) | | $0.45 million | View | N/A | |
| 3/24/2016 | Q4 | ($2.35) | ($1.10) | | $242.00 million | View | N/A | |
| 11/12/2015 | Q3 2015 | | ($1.65) | | $0.25 million | View | N/A | |
| 8/7/2015 | Q215 | ($1.10) | $1.25 | | $0.10 million | View | N/A | |
| 5/4/2015 | Q1 2015 | | ($8.35) | | $0.02 million | View | N/A | |
| 3/10/2015 | Q4 2014 | | ($11.15) | | | View | N/A | |
| 12/18/2014 | Q3 2014 | | ($22.35) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Soleno Therapeutics (NASDAQ:SLNO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Soleno Therapeutics (NASDAQ SLNO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 69.75%
Institutional Ownership Percentage: 45.79%
Soleno Therapeutics (NASDAQ SLNO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Larry N Feinberg | Major Shareholder | Buy | 50,000 | $1.80 | $90,000.00 | | |
| 12/15/2017 | Edgar Engleman | Director | Buy | 1,085,480 | $1.84 | $1,997,283.20 | | |
| 8/19/2016 | Bhatnagar Anish | Insider | Buy | 10,000 | $0.96 | $9,600.00 | 83,419 | |
| 8/18/2016 | David D O'toole | Insider | Buy | 2,000 | $1.01 | $2,020.00 | 44,750 | |
| 8/18/2016 | Ernest Mario | Director | Buy | 25,000 | $0.99 | $24,750.00 | 1,763,637 | |
| 8/17/2016 | David D O'toole | Insider | Buy | 10,000 | $0.92 | $9,200.00 | 42,750 | |
| 6/8/2016 | Ernest Mario | Director | Buy | 50,000 | $1.24 | $62,000.00 | 1,918,637 | |
| 5/23/2016 | Steinar J Engelsen | Director | Buy | 58,200 | $1.31 | $76,242.00 | 80,960 | |
| 5/20/2016 | Ernest Mario | Director | Buy | 48,806 | $1.18 | $57,591.08 | 1,863,000 | |
| 5/13/2016 | Bhatnagar Anish | CEO | Buy | 5,000 | $1.15 | $5,750.00 | 73,419 | |
| 5/12/2016 | David D O'toole | Insider | Buy | 5,000 | $1.16 | $5,800.00 | 32,750 | |
| 11/18/2015 | Ernest Mario | Director | Buy | 50,000 | $1.77 | $88,500.00 | 1,639,831 | |
| 11/17/2015 | David D O'toole | CFO | Buy | 5,000 | $1.79 | $8,950.00 | 27,750 | |
| 9/14/2015 | David D O'toole | CFO | Buy | 7,500 | $2.38 | $17,850.00 | 22,750 | |
| 9/14/2015 | Ernest Mario | Director | Buy | 15,000 | $2.28 | $34,200.00 | 1,589,831 | |
| 3/13/2015 | David D O'toole | CFO | Buy | 5,250 | $6.23 | $32,707.50 | | |
(Data available from 1/1/2013 forward)
Soleno Therapeutics (NASDAQ SLNO) News Headlines
| Source: |
|
Soleno Therapeutics (NASDAQ:SLNO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Soleno Therapeutics (NASDAQ:SLNO) Income Statement, Balance Sheet and Cash Flow Statement
Soleno Therapeutics (NASDAQ SLNO) Stock Chart for Thursday, May, 24, 2018
Loading chart…
